Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials

BACKGROUND: The efficacy of biologic therapies is greater among biologic‐naïve vs. biologic‐experienced psoriasis patients. However, little is known as to whether prior use of other systemic therapies impacts secukinumab efficacy in patients with moderate‐to‐severe psoriasis. OBJECTIVE: To investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Hampton, P., Halliday, A., Aassi, M., Subramanian, S., Jain, M., Griffiths, C.E.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986672/
https://www.ncbi.nlm.nih.gov/pubmed/33030755
http://dx.doi.org/10.1111/jdv.16982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986672/
https://www.ncbi.nlm.nih.gov/pubmed/33030755
http://dx.doi.org/10.1111/jdv.16982

Ejemplares similares